Neovantage Bio-Technology Profile
Key Indicators
- Authorised Capital ₹ 12.50 Cr
as on 10-12-2024
- Paid Up Capital ₹ 9.82 Cr
as on 10-12-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 63.00 Cr
as on 10-12-2024
- Satisfied Charges ₹ 361.60 Cr
as on 10-12-2024
- Revenue 146.35%
(FY 2022)
- Profit -21.34%
(FY 2022)
- Ebitda 114.08%
(FY 2022)
- Net Worth -22.21%
(FY 2022)
- Total Assets -8.00%
(FY 2022)
About Neovantage Bio-Technology
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 12.50 Cr and a paid-up capital of Rs 9.82 Cr.
The company currently has active open charges totaling ₹63.00 Cr. The company has closed loans amounting to ₹361.60 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shilpi Chowdhary and Chandan Mishra serve as directors at the Company.
- CIN/LLPIN
U74999TG2016PTC110776
- Company No.
110776
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jul 2016
- Date of AGM
26 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Neovantage Bio-Technology?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shilpi Chowdhary  | Director | 10-Jul-2018 | Current |
| Chandan Mishra | Additional Director | 17-Oct-2024 | Current |
Financial Performance and Corporate Structure Insights of Neovantage Bio-Technology.
Neovantage Bio-Technology Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 146.35% increase. The company also saw a substantial fall in profitability, with a 21.34% decrease in profit. The company's net worth observed a substantial decline by a decrease of 22.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neovantage Bio-Technology?
In 2021, Neovantage Bio-Technology had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lhc Asset And Project Managers Private LimitedActive 5 years 8 monthsShilpi Chowdhary is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Hongkong And Shanghai Banking Corporation Limited Creation Date: 31 Oct 2022 | ₹63.00 Cr | Open |
Others Creation Date: 17 Dec 2019 | ₹69.60 Cr | Satisfied |
Others Creation Date: 07 Sep 2018 | ₹70.00 Cr | Satisfied |
How Many Employees Work at Neovantage Bio-Technology?
Unlock and access historical data on people associated with Neovantage Bio-Technology, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neovantage Bio-Technology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neovantage Bio-Technology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
